<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01449955</url>
  </required_header>
  <id_info>
    <org_study_id>08-049</org_study_id>
    <nct_id>NCT01449955</nct_id>
  </id_info>
  <brief_title>Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory</brief_title>
  <official_title>mTOR Kinase as a Therapeutic Target in Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>North Texas Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed study is to determine if pairing reactivation of a traumatic
      memory with a single administration of Rapamycin (e.g., Sirolimus) in men with combat-related
      Posttraumatic Stress Disorder leads to a reduction of the emotional strength of that
      particular traumatic memory.

      The following hypotheses will be tested:

        1. Traumatic memory reactivation paired with a single dose of Rapamycin will decrease
           objective measures of stress and self-report of stress during replay of the traumatic
           memory, relative to, subjects receiving placebo.

        2. Pairing administration of Rapamycin with traumatic memory reactivation will decrease
           symptoms of Posttraumatic Stress Disorder one month and three months later, relative to
           patients receiving placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-traumatic stress disorder (PTSD) is characterized by intrusive memories in the form of
      unwanted images, nightmares, and flashbacks as the result of being exposed to a traumatic
      event . Current research efforts have begun to explore the underlying neurochemical changes
      associated with PTSD. Recently, these efforts have focused on the prevention of PTSD in
      persons exposed to trauma. For example, preliminary evidence suggests that interference with
      consolidation of trauma-related memories using the beta-antagonist, propranolol, may prevent
      PTSD in humans with recent traumas. However, given that as much as 90% of the US population
      is exposed to at least one traumatic event during their lifetimes, the utility of this
      treatment is limited by the logistical problems of treating everyone at risk. To date, there
      have been very few systematic studies on humans that focus on changing the underlying
      traumatic memory once PTSD has been established.

      The trauma experience is initially stored in short-term memory, then consolidated into
      long-term memory. However, the long-term stability conferred by the consolidation process
      undergoes a period of labiality as follows. Each time a consolidated memory is activated, the
      memory trace becomes newly labile and must be consolidated again to remain in long-term
      memory5. This process is called reconsolidation. Reconsolidation therefore offers a biologic
      window during which long-term memories can be disrupted. Preclinical studies have begun to
      unravel the biological changes that underlie these processes. Both pharmacological agents,
      including glucocorticoids, and protein synthesis inhibitors can interfere with memory
      consolidation and reconsolidation. In preclinical studies, the global protein synthesis
      inhibitor anisomycin can block reconsolidation, leading to a reduction in strength of
      traumatic memories. Unfortunately, the toxicity of anisomycin is prohibitive for therapeutic
      use. Thus, rather than using a global protein synthesis inhibitor, a more effective and
      selective means of reducing consolidation of an established traumatic memory is to target
      only a subset of protein translation important for synaptic plasticity. The protein kinase
      mTOR (mammalian target of rapamycin) is just such a regulator of a subset of protein
      synthesis critical for synaptic plasticity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</measure>
    <time_frame>Baseline and 1 month posttreatment</time_frame>
    <description>Clinician administered interview which assesses the symptoms of Posttraumatic Stress disorder at baseline, and then again 1 month posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</measure>
    <time_frame>change in CAPS score from baseline to 3 months posttreatment</time_frame>
    <description>The CAPS is administered to assess the frequency and intensity of PTSD symptoms at baseline, and then again 3 months posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist (PCL)</measure>
    <time_frame>change in PCL score from baseline to 1 month posttreatment</time_frame>
    <description>Self-report instrument which assesses the intensity of Posttraumatic Stress Disorder symptoms. The PCL measures the 17 DSM-IV PTSD criteria in 17 items. For each item the participant can respond with a rating of 1-5 (with 1 indicating not at all bothered 5 indicating extremely bothered by the symptom) The range of total scores on the PCL is from 17-85, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSD Checklist (PCL)</measure>
    <time_frame>change in PCL score from baseline to 3 months posttreatment</time_frame>
    <description>Self-report instrument which assesses the intensity of Posttraumatic Stress Disorder symptoms. The PCL measures the 17 DSM-IV PTSD criteria in 17 items. For each item the participant can respond with a rating of 1-5 (with 1 indicating not at all bothered 5 indicating extremely bothered by the symptom) The range of total scores on the PCL is from 17-85, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology (QIDS)</measure>
    <time_frame>change in QIDS score from baseline to 1 month posttreatment</time_frame>
    <description>The QIDS is a 16-item self-report measure that assesses how much a participant endorses each of the DSM-IV-TR symptoms of depression, with each item scored from 0 (no endorsement of symptom) to 3 (endorsement of severe symptomatology). Scores on the QIDS range from 0-27, with higher scores indicating higher depressive symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptomatology (QIDS)</measure>
    <time_frame>change in QIDS score from baseline to 3 months posttreatment</time_frame>
    <description>The QIDS is a 16-item self-report measure that assesses how much a participant endorses each of the DSM-IV-TR symptoms of depression, with each item scored from 0 (no endorsement of symptom) to 3 (endorsement of severe symptomatology). Scores on the QIDS range from 0-27, with higher scores indicating higher depressive symptom severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo (e.g., sugar pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>15 mg Placebo will be administered once, in pill form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg of Rapamycin will be administered once, in pill form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.
a single dosage of 15mg will be administered during this study.</description>
    <arm_group_label>Rapamycin</arm_group_label>
    <other_name>Sirolimus</other_name>
    <other_name>X-Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive</description>
    <arm_group_label>Placebo (e.g., sugar pill)</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male Veterans

          -  Diagnosis of Posttraumatic Stress Disorder related to combat

        Exclusion Criteria:

          -  Hypersensitivity to Rapamycin

          -  Organic brain damage (including unresolved Traumatic Brain Injury sequela)

          -  Substance dependence in the last three months

          -  On any immunosuppressant therapy

          -  Prominent suicidal or homicidal features

          -  Medical conditions: systemic infections, congestive heart failure, renal failure,
             hepatic failure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alina M Suris, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center; VA North Texas Healthcare System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carol North, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UT Southwestern Medical Center; VA North Texas Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA North Texas Healthcare System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blundell J, Kouser M, Powell CM. Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol Learn Mem. 2008 Jul;90(1):28-35. doi: 10.1016/j.nlm.2007.12.004. Epub 2008 Mar 7.</citation>
    <PMID>18316213</PMID>
  </reference>
  <results_reference>
    <citation>Sur√≠s A, Smith J, Powell C, North CS. Interfering with the reconsolidation of traumatic memory: sirolimus as a novel agent for treating veterans with posttraumatic stress disorder. Ann Clin Psychiatry. 2013 Feb;25(1):33-40.</citation>
    <PMID>23376868</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 16, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2011</study_first_posted>
  <results_first_submitted>June 18, 2013</results_first_submitted>
  <results_first_submitted_qc>December 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2014</results_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Alina Suris</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited by flyers, clinician referral and letters mailed to male VA North Texas patients with PTSD.</recruitment_details>
      <pre_assignment_details>excluded if did not meet PTSD criteria according to the CAPS</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rapamycin (e.g., Sirolimus)</title>
          <description>15mg Rapamycin administered once in pill form</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>15mg Placebo administered once in pill form</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Male Veterans with PTSD</population>
      <group_list>
        <group group_id="B1">
          <title>Rapamycin</title>
          <description>15mg Rapamycin administered once in pill form</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>15mg Placebo administered once in pill form</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.64" spread="14.39"/>
                    <measurement group_id="B2" value="42.15" spread="15.46"/>
                    <measurement group_id="B3" value="42.21" spread="14.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</title>
        <description>Clinician administered interview which assesses the symptoms of Posttraumatic Stress disorder at baseline, and then again 1 month posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.</description>
        <time_frame>Baseline and 1 month posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin (e.g., Sirolimus)</title>
            <description>15mg Rapamycin administered once in pill form</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>15 mg Placebo administered once in pill form</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</title>
          <description>Clinician administered interview which assesses the symptoms of Posttraumatic Stress disorder at baseline, and then again 1 month posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.13" spread="15.27"/>
                    <measurement group_id="O2" value="70.63" spread="16.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month posttreatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.27" spread="22.96"/>
                    <measurement group_id="O2" value="64.54" spread="17.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANOVA comparing the results of change over time (e.g., comparing baseline to 1 month posttreatment) as well as comparing differences between condition (e.g., placebo compared to rapamycin).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</title>
        <description>The CAPS is administered to assess the frequency and intensity of PTSD symptoms at baseline, and then again 3 months posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.</description>
        <time_frame>change in CAPS score from baseline to 3 months posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin (e.g., Sirolimus) Baseline</title>
            <description>15mg Rapamycin administered once in pill form at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo at Baseline</title>
            <description>15 mg Placebo administered once in pill form at baseline</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin (e.g., Sirolimus) at 3 Months Posttreatment</title>
            <description>15mg Rapamycin administered once in pill form at 3 months Posttreatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months Posttreatment</title>
            <description>15 mg Placebo administered once in pill form at 3 months posttreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</title>
          <description>The CAPS is administered to assess the frequency and intensity of PTSD symptoms at baseline, and then again 3 months posttreatment. The CAPS is a 25 item semi-structured interview that assesses the 17 DSM-IV PTSD criteria as well as social and occupational impairment. For each item the participant can respond with a rating of 0-8 (with 0 indicating no symptom severity and frequency and 8 indicating extreme symptom severity and frequency). The range of total scores on a CAPS is from 0-136, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items. Additionally, the CAPS assesses for a positive PTSD diagnosis by assessing for the three DSM-IV criteria of B, C, and D. In order to meet a positive screen for each criteria, a person must screen positive for symptoms by reporting a score of 3 or more on the specific symptom criterion.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.13" spread="15.27"/>
                    <measurement group_id="O2" value="70.63" spread="16.37"/>
                    <measurement group_id="O3" value="55.26" spread="22.62"/>
                    <measurement group_id="O4" value="62.63" spread="17.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.5</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist (PCL)</title>
        <description>Self-report instrument which assesses the intensity of Posttraumatic Stress Disorder symptoms. The PCL measures the 17 DSM-IV PTSD criteria in 17 items. For each item the participant can respond with a rating of 1-5 (with 1 indicating not at all bothered 5 indicating extremely bothered by the symptom) The range of total scores on the PCL is from 17-85, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items.</description>
        <time_frame>change in PCL score from baseline to 1 month posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin (e.g., Sirolimus) Baseline</title>
            <description>15mg Rapamycin administered once in pill form at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo at Baseline</title>
            <description>15 mg Placebo administered once in pill form at baseline</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin (e.g., Sirolimus) at 1 Month Posttreatment</title>
            <description>15mg Rapamycin administered once in pill form at 1 month Posttreatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 1 Month Posttreatment</title>
            <description>15 mg Placebo administered once in pill form at 1 month Posttreatment</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist (PCL)</title>
          <description>Self-report instrument which assesses the intensity of Posttraumatic Stress Disorder symptoms. The PCL measures the 17 DSM-IV PTSD criteria in 17 items. For each item the participant can respond with a rating of 1-5 (with 1 indicating not at all bothered 5 indicating extremely bothered by the symptom) The range of total scores on the PCL is from 17-85, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.19" spread="10.61"/>
                    <measurement group_id="O2" value="60.83" spread="10.26"/>
                    <measurement group_id="O3" value="49.62" spread="13.14"/>
                    <measurement group_id="O4" value="55.00" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSD Checklist (PCL)</title>
        <description>Self-report instrument which assesses the intensity of Posttraumatic Stress Disorder symptoms. The PCL measures the 17 DSM-IV PTSD criteria in 17 items. For each item the participant can respond with a rating of 1-5 (with 1 indicating not at all bothered 5 indicating extremely bothered by the symptom) The range of total scores on the PCL is from 17-85, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items.</description>
        <time_frame>change in PCL score from baseline to 3 months posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin (e.g., Sirolimus) Baseline</title>
            <description>15mg Rapamycin administered once in pill form at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo at Baseline</title>
            <description>15 mg Placebo administered once in pill form at baseline</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin (e.g., Sirolimus) at 3 Months Posttreatment</title>
            <description>15mg Rapamycin administered once in pill form at 3 months posttreatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months Posttreatment</title>
            <description>15 mg Placebo administered once in pill form at 3 months posttreatment</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Checklist (PCL)</title>
          <description>Self-report instrument which assesses the intensity of Posttraumatic Stress Disorder symptoms. The PCL measures the 17 DSM-IV PTSD criteria in 17 items. For each item the participant can respond with a rating of 1-5 (with 1 indicating not at all bothered 5 indicating extremely bothered by the symptom) The range of total scores on the PCL is from 17-85, with a greater score indicating greater PTSD symptom severity. The total score is computed by summing the aforementioned 17 items.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.19" spread="10.61"/>
                    <measurement group_id="O2" value="60.83" spread="10.26"/>
                    <measurement group_id="O3" value="51.07" spread="13.81"/>
                    <measurement group_id="O4" value="54.13" spread="11.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptomatology (QIDS)</title>
        <description>The QIDS is a 16-item self-report measure that assesses how much a participant endorses each of the DSM-IV-TR symptoms of depression, with each item scored from 0 (no endorsement of symptom) to 3 (endorsement of severe symptomatology). Scores on the QIDS range from 0-27, with higher scores indicating higher depressive symptom severity.</description>
        <time_frame>change in QIDS score from baseline to 1 month posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin (e.g., Sirolimus) Baseline</title>
            <description>15mg Rapamycin administered once in pill form at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo at Baseline</title>
            <description>15 mg Placebo administered once in pill form at baseline</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin (e.g., Sirolimus) at 1 Month Posttreatment</title>
            <description>15mg Rapamycin administered once in pill form at 1 month Posttreatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 1 Month Posttreatment</title>
            <description>15 mg Placebo administered once in pill form at 1 month Posttreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology (QIDS)</title>
          <description>The QIDS is a 16-item self-report measure that assesses how much a participant endorses each of the DSM-IV-TR symptoms of depression, with each item scored from 0 (no endorsement of symptom) to 3 (endorsement of severe symptomatology). Scores on the QIDS range from 0-27, with higher scores indicating higher depressive symptom severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.48" spread="3.97"/>
                    <measurement group_id="O2" value="13.79" spread="4.45"/>
                    <measurement group_id="O3" value="11.27" spread="5.03"/>
                    <measurement group_id="O4" value="11.75" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; .05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quick Inventory of Depressive Symptomatology (QIDS)</title>
        <description>The QIDS is a 16-item self-report measure that assesses how much a participant endorses each of the DSM-IV-TR symptoms of depression, with each item scored from 0 (no endorsement of symptom) to 3 (endorsement of severe symptomatology). Scores on the QIDS range from 0-27, with higher scores indicating higher depressive symptom severity.</description>
        <time_frame>change in QIDS score from baseline to 3 months posttreatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rapamycin (e.g., Sirolimus) Baseline</title>
            <description>15mg Rapamycin administered once in pill form at baseline</description>
          </group>
          <group group_id="O2">
            <title>Placebo at Baseline</title>
            <description>15 mg Placebo administered once in pill form at baseline</description>
          </group>
          <group group_id="O3">
            <title>Rapamycin (e.g., Sirolimus) at 3 Months Posttreatment</title>
            <description>15mg Rapamycin administered once in pill form at 3 months Posttreatment</description>
          </group>
          <group group_id="O4">
            <title>Placebo at 3 Months Posttreatment</title>
            <description>15 mg Placebo administered once in pill form at 3 months posttreatment</description>
          </group>
        </group_list>
        <measure>
          <title>Quick Inventory of Depressive Symptomatology (QIDS)</title>
          <description>The QIDS is a 16-item self-report measure that assesses how much a participant endorses each of the DSM-IV-TR symptoms of depression, with each item scored from 0 (no endorsement of symptom) to 3 (endorsement of severe symptomatology). Scores on the QIDS range from 0-27, with higher scores indicating higher depressive symptom severity.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.48" spread="3.97"/>
                    <measurement group_id="O2" value="13.79" spread="4.45"/>
                    <measurement group_id="O3" value="11.56" spread="5.13"/>
                    <measurement group_id="O4" value="11.29" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; .05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rapamycin</title>
          <description>15mg Rapamycin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Timing of medication administration may not have been optimal and relatively small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alina Suris</name_or_title>
      <organization>UT Southwestern/VA North Texas</organization>
      <phone>214-857-0334</phone>
      <email>alina.suris@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

